RESUMO
Plasma levels of the platelet markers betathromboglobulin and platelet factor 4 are elevated in patients with chronic renal failure, and their levels in hemodialysis patients increase further during exposure to the dialysis membrane. The effectiveness of a short acting inhibitor of platelet aggregation in reducing the blood levels of betathromboglobulin and platelet factor 4 was assessed by means of a double blind cross over study. A statistically significant reduction of betathromboglobulin and platelet factor 4 levels was observed during treatment with the platelet inhibitor.
Assuntos
beta-Globulinas/análise , Fatores de Coagulação Sanguínea/análise , Fenilbutiratos/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Fator Plaquetário 4/análise , Diálise Renal , beta-Tromboglobulina/análise , Adulto , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Humanos , Isoindóis , Falência Renal Crônica/sangue , Falência Renal Crônica/terapia , Masculino , Pessoa de Meia-IdadeRESUMO
The effect of a single dose of indobufen (100 mg i.v.) on the release of beta-thromboglobulin and of the platelet factor 4 was investigated during dialysis in 20 uraemic subjects by a within-subjects, single-blind, indobufen versus placebo study. Plasma levels were measured in baseline conditions and 15, 30, 60, 120 and 240 minutes after the beginning of dialysis. Pre-treatment with indobufen clearly inhibited beta-TG and PF 4 output. The difference from placebo was highly significant (p less than 0.01) from the 30-minute control up to the end of dialysis. No changes in platelet count before and after dialysis were observed.